Skip to main content

Table 2 Characteristics of the 15 Cavitary Adenocarcinoma patients with EGFR mutations

From: Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Patient No.

Age, y

Gender

Smoking

Stage

Tumor size

Wall

EGFR mutations

EGFR-TKI

PFS, mo

Efficacy

T790 M

1

62

Male

Never

IV

2.6 cm

Thick

L858R mutation

Erlotinib

4.7

SD

Unknown

2

71

Male

Never

IV

3.6 cm

Thick

L858R mutation

Gefitinib

3.3

PR

Negative

3

52

Female

Never

IV

2.2 cm

Thick

L858R mutation

Gefitinib

6.0

PR

Negative

4

44

Male

Never

IV

2.4 cm

Thick

L858R mutation

Gefitinib

9.6

PR

Positive

5

57

Male

Never

IV

2.0 cm

Thick

L858R mutation

Gefitinib

1.0

PD

Negative

6

50

Male

Smoker

IV

2.6 cm

Thick

L858R mutation

Erlotinib

4.2

SD

Unknown

7

76

Female

Never

IV

5.0 cm

Thick

Exon 19 deletion

Gefitinib

5.2

SD

Unknown

8

37

Female

Never

IV

2.8 cm

Thin

Exon 19 deletion

Icotinib

11.4

PR

Unknown

9

75

Male

Never

IV

2.2 cm

Thin

Exon 19 deletion

Icotinib

11.0

PR

Positive

10

61

Female

Never

IV

2.2 cm

Thin

Exon 19 deletion

Gefitinib

24.5

PR

Positive

11

47

Male

Smoker

IV

4.5 cm

Thick

Exon 19 deletion

Gefitinib

6.7

PR

Negative

12

48

Male

Never

IV

2.2 cm

Thick

Exon 19 deletion

Gefitinib

6.5

SD

Negative

13

51

Male

Smoker

IV

4.8 cm

Thin

Exon 19 deletion

Icotinib

9.7

SD

Negative

14

56

Female

Never

Recurrent

2.0 cm

Thin

Exon 19 deletion

Gefitinib

4.5

PR

Positive

15

39

Male

Smoker

IV

2.5 cm

Thin

Exon 19 deletion

Icotinib

3.0

SD

Unknown

  1. Abbreviations: EGFR-TKI epidermal growth factor receptor- tyrosine kinase inhibitor, ECOG PS Eastern Corporation Oncology Group performance status, SD standard deviation, PR partial response, SD stable disease, PD progressive disease, PFS median progression-free survival